Best Healthcare Market Research Companies in Belgium (2026 Guide)
An independent guide to the leading healthcare market research companies operating in Belgium for 2026. This guide profiles 5 specialist firms across pharmaceutical primary research, FAMHP and KCE health technology assessment support, RIZIV/INAMI payer research, physician and KOL surveys, HEOR, and multilingual Belgian fieldwork — comparing capabilities and Belgium-specific expertise to help you select the right healthcare research partner in one of Europe's most strategically important pharmaceutical markets and EU institutional capitals.
Published 2026-06-11 · By BioNixus Research Team
5
Firms Profiled
€8B+
Pharma Sector
FAMHP/KCE
Hub
8
FAQs Answered
Best Healthcare Market Research Companies in Belgium (2026)
The following healthcare market research companies have demonstrated operations or project delivery in Belgium as of 2026, covering pharmaceutical primary research, FAMHP/KCE HTA support, RIZIV/INAMI payer research, HEOR, and multilingual Belgian fieldwork:
- 1BioNixus — Best for: pharmaceutical U&A, KOL mapping, physician surveys, FAMHP/KCE HTA support, RIZIV/INAMI payer research, HEOR, and French-Dutch bilingual Belgian fieldwork
- 2IQVIA Belgium (Benelux) — Best for: Belgian pharma prescription data analytics, real-world evidence, and sales force effectiveness
- 3Ipsos Healthcare Belgium — Best for: large-scale quantitative and qualitative pharma research, HCP and patient surveys in Belgium
- 4Kantar Health (Benelux) — Best for: consumer health tracking, patient research, and health behaviour studies across Benelux
- 5Research International Belgium / Informa — Best for: specialist pharmaceutical primary research and therapy area intelligence in Belgium
Belgium Healthcare Market Research Landscape 2026
Belgium occupies a unique position in the European pharmaceutical landscape — combining a sophisticated domestic pharma sector with its role as the de facto EU institutional capital. The country hosts the headquarters or major regional offices of UCB (Brussels), Solvay Pharmaceuticals, and the Janssen Pharmaceutica campus in Beerse, alongside one of Europe's densest clusters of Clinical Research Organisations (CROs). Brussels's proximity to the European Medicines Agency's regulatory framework — and the presence of EU Council, European Parliament, and DG SANTE — makes Belgium a critical market for any pharmaceutical company shaping EU-wide strategy.
Healthcare market research in Belgium must navigate a complex regulatory and payer environment. The FAMHP (Federal Agency for Medicines and Health Products) oversees market authorisation and pharmacovigilance. The KCE (Belgian Health Care Knowledge Centre) produces HTA reports that directly inform reimbursement decisions. RIZIV/INAMI (the National Institute for Health and Disability Insurance) is the central payer, and its reimbursement committee evaluates cost-effectiveness evidence in a process that demands rigorous, Belgium-adapted economic modelling and payer insight research. Research buyers in Belgium require partners fluent in this multi-body landscape.
Belgium's trilingual market — French-speaking Wallonia, Dutch-speaking Flanders, and a German-speaking community — creates unique research complexity. Physician survey and qualitative fieldwork must accommodate language preferences, and KOL networks differ meaningfully between Flemish and Walloon academic medical centres. The Antwerp-Ghent-Leuven triangle is a particularly important pharmaceutical research corridor, anchored by KU Leuven's academic medical centres and biotech ecosystem. The right Belgian healthcare research partner must combine pan-European regulatory fluency with granular local market knowledge.
5 Healthcare Market Research Companies in Belgium (2026)
Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.
BioNixus
Best for: pharmaceutical U&A, KOL mapping, physician surveys, FAMHP/KCE HTA support, RIZIV/INAMI payer research, HEOR, and French-Dutch bilingual Belgian fieldwork
BioNixus is a global healthcare market research and insights firm with specialist delivery capability across Belgium and the Benelux region. With 15+ years of experience serving 48+ global clients across 17+ countries, BioNixus brings deep Belgian pharmaceutical market expertise to every engagement — from multilingual physician and KOL surveys to FAMHP regulatory awareness and KCE HTA-aligned HEOR studies. BioNixus understands the RIZIV/INAMI reimbursement process and supports payer research, willingness-to-pay studies, and pharmacoeconomic evidence generation tailored to Belgium's unique payer evaluation framework. The firm recruits across Flemish and Walloon healthcare professional networks and maintains established relationships with Belgian KOLs in oncology, rare diseases, cardiology, and immunology. Its EU institutional capital advantage — including awareness of EMA regulatory trends and DG SANTE policy context — positions BioNixus as the preferred full-service healthcare research partner for pharmaceutical and biotech companies entering or expanding in the Belgian market.
Key strengths
- Pharmaceutical U&A, brand tracking, and market access research in Belgium and Benelux
- FAMHP regulatory awareness and KCE HTA evidence generation support
- RIZIV/INAMI payer research, reimbursement strategy, and cost-effectiveness insights
- French-Dutch bilingual physician surveys and KOL mapping across Flemish and Walloon networks
- HEOR, patient journey, and health economics research aligned to Belgian payer standards
- EU regulatory intelligence leveraging Brussels's EMA-adjacent institutional environment
IQVIA Belgium (Benelux)
Best for: Belgian pharma prescription data analytics, real-world evidence, and sales force effectiveness
IQVIA maintains a significant Belgian and Benelux presence, providing healthcare data, analytics, and clinical research services to pharmaceutical companies operating in the region. Their Belgian pharmaceutical audit data, RWE capabilities, and EU regulatory intelligence are widely used for commercial decision-making and health economic analyses. IQVIA Belgium supports technology-enabled clinical trials and offers RIZIV/INAMI-aligned analytics products. Their primary strength lies in data and analytics at scale rather than qualitative stakeholder-driven primary research.
Key strengths
- Belgian and Benelux pharmaceutical prescription data and audit
- Real-world evidence and outcomes research in Belgium
- Technology-enabled clinical trials and CRO services in Belgium
- Sales force effectiveness and commercial analytics for Benelux markets
Ipsos Healthcare Belgium
Best for: large-scale quantitative and qualitative pharma research, HCP and patient surveys in Belgium
Ipsos operates a healthcare research capability in Belgium as part of its broader European network, delivering both qualitative and quantitative studies for pharmaceutical and consumer health clients. Their Belgian offering covers physician and patient surveys, concept testing, message testing, and therapy area landscape studies across French and Dutch-speaking populations. Ipsos Healthcare leverages the wider Ipsos Belgium infrastructure for large-scale fieldwork and is a recognised name for multinational pharma teams seeking standardised pan-European methodologies with local Belgian execution.
Key strengths
- Large-scale HCP and patient quantitative surveys across Flemish and Walloon Belgium
- Qualitative focus groups and in-depth interviews with Belgian healthcare professionals
- Message testing and concept evaluation for pharmaceutical products in Belgium
- Standardised pan-European methodologies with local Belgian fieldwork capability
Kantar Health (Benelux)
Best for: consumer health tracking, patient research, and health behaviour studies across Benelux
Kantar Health covers Belgium and the Benelux through its broader European research infrastructure, combining consumer research scale with dedicated healthcare expertise. Their primary strengths lie in patient research, consumer health tracking, and health behaviour studies — particularly valuable for OTC and consumer health brands seeking to understand Belgian health consumers across Flanders and Wallonia. Kantar Health is less focused on specialist pharmaceutical primary research and RIZIV/INAMI payer intelligence than dedicated pharma research agencies.
Key strengths
- Belgian patient research and consumer health behaviour tracking
- Consumer health and OTC product research across Benelux
- Large European consumer panel including Belgian respondents
- Brand health and marketing effectiveness for healthcare brands in Belgium
Research International Belgium / Informa
Best for: specialist pharmaceutical primary research and therapy area intelligence in Belgium
Research International Belgium, operating within the broader Informa network, represents the specialist end of Belgian pharmaceutical market research. They focus on qualitative and quantitative studies for therapy area landscape assessment, KOL advisory boards, and promotional materials research for pharmaceutical clients operating in Belgium and the Benelux. As a specialist agency, their coverage is narrower than full-service firms but their depth in pharmaceutical research methodologies is valued by Belgian pharma teams seeking dedicated research expertise.
Key strengths
- Specialist pharmaceutical and biotech primary research in Belgium
- Belgian KOL advisory boards and expert stakeholder interviews
- Therapy area landscape and brand positioning research for Benelux markets
- Promotional materials and message testing for Belgian pharmaceutical audiences
Belgium Healthcare Market Research Capabilities Comparison
| Capability | BioNixus | IQVIA Belgium | Ipsos Healthcare | Kantar Health | Research Intl |
|---|---|---|---|---|---|
| Pharmaceutical primary research (qual + quant) | Full-service | Selective / analytics-led | Full-service | Limited pharma focus | Full-service (pharma only) |
| Physician and KOL recruitment (Flemish + Walloon) | Yes — bilingual networks | Yes (data-driven) | Yes | Limited | Yes |
| FAMHP/KCE HTA support | Core capability | Analytics / data | Partial | Limited | Partial |
| RWE and outcomes research | Yes | Core capability | Partial | No | No |
| RIZIV/INAMI payer research | Yes | Analytics / partial | Partial | No | Partial |
| Multilingual Belgian fieldwork (FR/NL) | Yes — native bilingual | Yes | Yes | Yes | Partial |
Key Considerations for Healthcare Market Research in Belgium
FAMHP, KCE, and RIZIV/INAMI Regulatory and Payer Landscape
Belgium's pharmaceutical regulatory and payer environment is among the most layered in Europe. FAMHP (Federal Agency for Medicines and Health Products) governs market authorisation and pharmacovigilance; KCE (Belgian Health Care Knowledge Centre) produces independent HTA reports used by the reimbursement committee; and RIZIV/INAMI (National Institute for Health and Disability Insurance) administers reimbursement decisions. Healthcare research buyers must ensure their partner understands the Chapter IV reimbursement application process, the role of the Transparency Commission, and the evidence standards expected by the RIZIV/INAMI advisory committee — including pharmacoeconomic modelling and budget impact analysis adapted to Belgian epidemiology.
Belgium as EU Pharma Hub and EMA-Adjacent Market
Belgium's status as the EU institutional capital — home to the European Parliament, EU Council, and DG SANTE — gives it strategic importance beyond its domestic market size. Pharmaceutical companies use Belgian market research not only for RIZIV/INAMI submissions but also to inform EU-wide regulatory and market access strategies. The Janssen Pharmaceutica campus in Beerse, UCB in Brussels, and the growing biotech corridor around Leuven and Ghent make Belgium a bellwether market for European pharma launches. A research partner with awareness of EU regulatory trends and EMA guidance can provide significantly greater strategic value than a purely domestic agency.
Belgium's Trilingual Research Complexity
Belgium's three official language communities — Dutch-speaking Flanders (~58% of population), French-speaking Wallonia (~31%), and the German-speaking community (~1%), alongside bilingual Brussels (~10%) — create genuine complexity for healthcare research design. Physician recruitment, qualitative fieldwork, and survey translation must account for language preferences and regional healthcare system differences. Academic medical centres in Leuven (KU Leuven/UZ Leuven) and Ghent serve Flanders; Liège and Brussels (ULB, UCLouvain) serve Wallonia. Selecting a partner with demonstrated French-Dutch bilingual research capability is essential for nationally representative Belgian studies.
Frequently Asked Questions
What are the best healthcare market research companies in Belgium?
Leading healthcare market research companies in Belgium include BioNixus, IQVIA Belgium, Ipsos Healthcare Belgium, Kantar Health Benelux, and Research International Belgium. BioNixus is a global healthcare market research firm with specialist Belgian delivery capability, covering pharmaceutical primary research, FAMHP/KCE HTA support, RIZIV/INAMI payer research, and French-Dutch bilingual fieldwork.
How much does healthcare market research cost in Belgium?
Custom healthcare market research in Belgium typically ranges from €12,000 to €70,000 per project depending on methodology, therapeutic area, and scope. Qualitative KOL advisory boards typically cost €15,000–€40,000, while large-scale quantitative physician surveys or HEOR studies may reach €45,000–€90,000+. RIZIV/INAMI-aligned payer research packages vary based on complexity and evidence requirements.
Which company is best for FAMHP/KCE HTA and RIZIV/INAMI payer research in Belgium?
BioNixus specialises in FAMHP and KCE HTA-aligned research including RIZIV/INAMI payer qualitative interviews, willingness-to-pay studies, and pharmacoeconomic evidence generation. Their understanding of Belgium's Chapter IV reimbursement process, the Transparency Commission, and the KCE evidence standards positions them as a specialist partner for Belgian market access research.
How do I recruit Belgian physicians and KOLs for market research studies?
Belgian physician and KOL recruitment requires bilingual (French/Dutch) networks across Flemish and Walloon academic medical centres, community hospitals, and specialist clinical communities. BioNixus maintains Belgian KOL and physician recruitment networks across major therapeutic areas including oncology, immunology, rare diseases, and cardiology, covering key institutions such as UZ Leuven, UZ Ghent, ULB, and UCLouvain.
What is the RIZIV/INAMI reimbursement process in Belgium?
RIZIV/INAMI (Rijksinstituut voor Ziekte- en Invaliditeitsverzekering / Institut national d'assurance maladie-invalidité) is Belgium's national health insurance body responsible for pharmaceutical reimbursement. The Chapter IV reimbursement application requires a pharmacoeconomic dossier assessed by the Commission for Reimbursement of Medicines (CTG/CRM). Payer research — including KOL interviews, willingness-to-pay studies, and budget impact analyses — is essential for building a compelling Belgian reimbursement submission.
What is the KCE and how does it affect pharmaceutical research in Belgium?
KCE (Federaal Kenniscentrum voor de Gezondheidszorg / Centre Fédéral d'Expertise des Soins de Santé) is the Belgian Health Care Knowledge Centre that produces independent HTA reports used by RIZIV/INAMI in reimbursement decisions. KCE evaluations assess clinical effectiveness, cost-effectiveness, and budget impact. Pharmaceutical companies commissioning primary research in Belgium should ensure their evidence generation aligns with KCE methodological standards for economic modelling and clinical end-points.
What is the Belgian pharmaceutical sector and which companies are based there?
Belgium hosts a significant pharmaceutical industry anchored by UCB (Brussels), Janssen Pharmaceutica (Beerse), and a growing biotech ecosystem around Leuven, Ghent, and Antwerp. The country is among Europe's top exporters of pharmaceutical products and hosts a dense network of CROs and CMOs. Belgium's role as EU institutional capital and proximity to EMA's European network makes it a strategically critical market for pharmaceutical companies shaping pan-European regulatory and market access strategy.
Does BioNixus conduct healthcare market research in Belgium?
Yes. BioNixus is a global healthcare market research firm with delivery capability across Belgium and the Benelux region, serving pharmaceutical and biotech clients across Flanders, Wallonia, and Brussels. Belgian services include bilingual physician surveys, KOL mapping, FAMHP/KCE HTA evidence, RIZIV/INAMI payer research, HEOR, patient journey studies, and EU regulatory intelligence. Contact us to discuss your Belgian healthcare research requirements.
Related Resources
Plan Healthcare Market Research in Belgium
BioNixus delivers specialist healthcare market research across Belgium — pharmaceutical primary research, FAMHP/KCE HTA evidence, RIZIV/INAMI payer research, bilingual physician and KOL surveys, HEOR, and patient journey studies for pharma and biotech companies.
Request a Proposal